DOKTOR FALK FARMA GMBKH, PREDSTAVITELSTVO

The Liver Fibrosis market, valued at ~USD 2,308 million in 2023, is expected to grow significantly by 2034, driven by rising prevalence and new therapies. The US leads in market size and cases, with Germany leading in the EU. Key companies include Gilead Sciences, Pfizer, and AstraZeneca, focusing on emerging treatments like Efruxifermin and Aramchol.

The Eosinophilic Esophagitis (EoE) market, valued at ~USD 940 thousand million in 2023, is expected to grow significantly by 2034. EoE, a chronic inflammatory condition, affects 1 in 2,000 people, with the US having the highest cases. Treatments include DUPIXENT and JORVEZA, with ongoing research for better therapies.

The Eosinophilic Esophagitis (EoE) market, valued at ~USD 940 thousand million in 2023, is expected to grow significantly by 2034. Key developments include FDA approval of DUPIXENT for pediatric EoE treatment. The 7MM reported ~800,000 EoE cases in 2023, with the US leading. Treatments involve dietary changes, medications like PPIs, and emerging therapies.